Kelli L. Goss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kelli L. Goss has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- David J. Gordon
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa
63 shared publications - Stacia L. Koppenhafer
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
63 shared publications - Elizabeth L. Geary
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
48 shared publications - Emma E. Croushore
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa
48 shared publications - William W. Terry
Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Iowa City, Iowa
14 shared publications
Latest Publications
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Short-term gemcitabine drug treatment.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Short-term gemcitabine drug treatment.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Gemcitabine resistant cell lines.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Gemcitabine resistant cell lines.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Excel File 1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Quantification of immunoblots.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Excel File 1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Quantification of immunoblots.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Data from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. However, the polypharmacology and off-target effects of RNR inhibitors have complicated the identification of the mechanisms that regulate sensitivity and resistance to this class of drugs. Consequently, we used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identified that loss of the RRM1 protein results in the upregulation of the expression of multiple members of the activator protein-1 (AP-1) transcription factor complex, including c-Jun and c-Fos, and downregulation of c-Myc. Notably, overexpression of c-Jun and c-Fos in Ewing sarcoma cells is sufficient to inhibit cell growth and downregulate the expression of the c-Myc oncogene. We also identified that the upregulation of AP-1 is mediated, in part, by SLFN11, which is a replication stress response protein that is expressed at high levels in Ewing sarcoma. In addition, small-molecule inhibitors of RNR, including gemcitabine, and histone deacetylase inhibitors, which reduce the level of the RRM1 protein, also activate AP-1 signaling and downregulate the level of c-Myc in Ewing sarcoma. Overall, these results provide novel insight into the critical pathways activated by loss of RNR activity and the mechanisms of action of inhibitors of RNR.Significance:RNR is the rate-limiting enzyme in the synthesis of deoxyribonucleotides. Although RNR is the target of multiple chemotherapy drugs, polypharmacology and off-target effects have complicated the identification of the precise mechanism of action of these drugs. In this work, using a knockout-rescue approach, we identified that inhibition of RNR upregulates AP-1 signaling and downregulates the level of c-Myc in Ewing sarcoma tumors.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. However, the polypharmacology and off-target effects of RNR inhibitors have complicated the identification of the mechanisms that regulate sensitivity and resistance to this class of drugs. Consequently, we used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identified that loss of the RRM1 protein results in the upregulation of the expression of multiple members of the activator protein-1 (AP-1) transcription factor complex, including c-Jun and c-Fos, and downregulation of c-Myc. Notably, overexpression of c-Jun and c-Fos in Ewing sarcoma cells is sufficient to inhibit cell growth and downregulate the expression of the c-Myc oncogene. We also identified that the upregulation of AP-1 is mediated, in part, by SLFN11, which is a replication stress response protein that is expressed at high levels in Ewing sarcoma. In addition, small-molecule inhibitors of RNR, including gemcitabine, and histone deacetylase inhibitors, which reduce the level of the RRM1 protein, also activate AP-1 signaling and downregulate the level of c-Myc in Ewing sarcoma. Overall, these results provide novel insight into the critical pathways activated by loss of RNR activity and the mechanisms of action of inhibitors of RNR.Significance:RNR is the rate-limiting enzyme in the synthesis of deoxyribonucleotides. Although RNR is the target of multiple chemotherapy drugs, polypharmacology and off-target effects have complicated the identification of the precise mechanism of action of these drugs. In this work, using a knockout-rescue approach, we identified that inhibition of RNR upregulates AP-1 signaling and downregulates the level of c-Myc in Ewing sarcoma tumors.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Dependency of Ewing sarcoma cells on RRM1 and RRM2.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Dependency of Ewing sarcoma cells on RRM1 and RRM2.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Gene set enrichment analysis of genes up- and down-regulated in the EW8-RRM1-KO cells after removal of doxycycline.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Gene set enrichment analysis of genes up- and down-regulated in the EW8-RRM1-KO cells after removal of doxycycline.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Short-term gemcitabine drug treatment.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Short-term gemcitabine drug treatment.
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Increase in mRNA expression levels of AP-1 family members in RRM1-KO cell lines after removal of doxycycline and loss of the RRM1 protein
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Increase in mRNA expression levels of AP-1 family members in RRM1-KO cell lines after removal of doxycycline and loss of the RRM1 protein
- Open Access
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Treatment of EW8-RRM1-KO cells with prexasertib.
- 17 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress
Treatment of EW8-RRM1-KO cells with prexasertib.